What are the side effects of Tremelimumab?

Tremelimumab (Tremelimumab) is a CTLA-4 immune checkpoint inhibitor. Its mechanism of action determines that the drug may cause adverse reactions related to immune activation. Unlike traditional chemotherapy drugs, the side effects of temtumumab are not direct damage to cells, but are caused by the activation of the immune system, resulting in an excessive immune response against one's own tissues. These immune-related side effects (irAEs) are common in immunotherapy drugs and usually involve multiple organ systems such as the skin, liver, intestines, and endocrine system.

One of the most common side effects is skin reactions, including rash, itching, dry skin, etc. Most cases are mild and can be relieved by oral antihistamines or topical drugs. However, if a large area of u200bu200bu200bu200brash or peeling occurs, the drug needs to be stopped promptly and immunosuppressive treatment is required. Another type of more typical adverse reactions is digestive system problems, such as diarrhea, abdominal pain, nausea or enteritis. These symptoms often indicate the occurrence of immune colitis, and early intervention is needed to avoid serious complications.

Regarding liver function, temsitumumab may cause immune-related hepatitis, manifested by elevated transaminases or jaundice. This reaction usually occurs in the early stages of treatment, and regular monitoring of liver function is a necessary protective measure. For the endocrine system, temsitumumab sometimes causes thyroid dysfunction or adrenal insufficiency. These changes can lead to symptoms such as fatigue, weight changes, or hypotension, requiring long-term monitoring of hormone levels and replacement therapy.

In addition, some patients may develop rare but serious side effects such as immune pneumonitis or nephritis. If this type of reaction can be recognized early and glucocorticoids or immunomodulatory drugs are applied promptly, most patients can return to normal functions. It is worth noting that when temsilimumab is used in combination with durvalumab, the incidence of adverse reactions may be slightly higher than that of monotherapy, but most of them are within the controllable range.

Reference: https://www.drugs.com/mtm/tremelimumab.html